![Tomas Jan Heyman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tomas Jan Heyman
Directeur/Membre du Conseil chez
EXELIXIS, INC.
Fortune : 3 M $ au 31/05/2026
Profil
Tomas Jan Heyman is currently Chief Executive Officer at Interlaken Therapeutics, Inc., Independent Director at Exelixis, Inc. since 2023, Director at Interuniversitair Micro-Electronica Centrum VZW since 2012, Director at Primmune Therapeutics, Inc., Independent Director at Legend Biotech Corp.
since 2022, and Executive Partner at Bioqube Ventures NV since 2020.
Former roles include Chairman & Chief Executive Officer at Janssen Pharmaceutica NV from 2008 to 2016, Non-Executive Chairman at Venatorx Pharmaceuticals, Inc. from 2023 to 2024, Independent Director at Invivyd, Inc. from 2021 to 2024, Independent Director at OptiNose, Inc. from 2020 to 2025, Director at CVRx, Inc., Director at International Biomedical Research Alliance, Independent Director at Xilio Therapeutics, Inc. from 2022 to 2024, Independent Director at Akero Therapeutics, Inc. from 2020 to 2025, Member-Supervisory Board at Crucell NV, President at Johnson & Johnson Innovation - JJDC, Inc., Vice President-Licensing at Ortho Pharmaceutical Corp., Global Head-Business Development at Janssen Global Services LLC from 1992 to 2015, and Global Head-Business Development at Johnson & Johnson from 2015 to 2019.
Education includes graduate degrees from Katholieke Universiteit Leuven and the University of Antwerp.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EXELIXIS, INC. 0,02 % | 27/05/2026 | 50 649 ( 0,02 % ) | 3 M $ | 31/05/2026 |
| 18/03/2026 | 14 196 ( 0 % ) | 192 782 $ | 31/05/2026 |
Postes actifs de Tomas Jan Heyman
| Sociétés | Poste | Début |
|---|---|---|
| LEGEND BIOTECH CORPORATION | Directeur/Membre du Conseil | 02/08/2022 |
| EXELIXIS, INC. | Directeur/Membre du Conseil | 31/05/2023 |
Interlaken Therapeutics, Inc. | Directeur Général | - |
Primmune Therapeutics, Inc.
 Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops orally administered toll-like receptor for cancer immunotherapy | Directeur/Membre du Conseil | - |
Interuniversitair Micro-Electronica Centrum VZW
 Interuniversitair Micro-Electronica Centrum VZW Miscellaneous Commercial ServicesCommercial Services Engages in research and development of nano electronics and digital technology products | Directeur/Membre du Conseil | 27/04/2012 |
Bioqube Ventures NV
 Bioqube Ventures NV Investment ManagersFinance Functions as an alternative investment manager | Private Equity Investor | 01/09/2020 |
Anciens postes connus de Tomas Jan Heyman
| Sociétés | Poste | Fin |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 09/12/2025 |
| OPTINOSE, INC. | Directeur/Membre du Conseil | 21/05/2025 |
| XILIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 13/06/2024 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Tomas Jan Heyman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
54
Relations au 1er degré
21
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 21 |
|---|---|
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Develops, produces and markets vaccines, proteins and antibodies | Health Technology |
OptiNose, Inc.
 OptiNose, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes products for patients treated by ear, nose, throat and allergy diseases | Health Technology |
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel anti-infectives to treat multi-drug-resistant bacterial and viral infections | Health Technology |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC invests in private and public companies located across the globe. The firm focuses on innovative medicine, health equity and medtech sectors. It provides financing for seed, early, and later stage capital requirements. | Finance |
CVRx, Inc.
 CVRx, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and commercializes neuromodulation device & implantable technology to treat hypertension and heart failure | Health Technology |
Katholieke Universiteit Leuven
 Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
International Biomedical Research Alliance
 International Biomedical Research Alliance Miscellaneous Commercial ServicesCommercial Services Provides doctoral training program for science students committed to biomedical research careers | Commercial Services |
Janssen Pharmaceutica NV
 Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Engages in research, development and production of drugs | Health Technology |
Ortho Pharmaceutical Corp. | |
Interuniversitair Micro-Electronica Centrum VZW
Interuniversitair Micro-Electronica Centrum VZW Miscellaneous Commercial ServicesCommercial Services Engages in research and development of nano electronics and digital technology products | Commercial Services |
University of Antwerp
 University of Antwerp Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Janssen Global Services LLC
 Janssen Global Services LLC Pharmaceuticals: MajorHealth Technology Develops treatments for patients in therapeutic areas of healthcare | Health Technology |
Legend Biotech Corp.
 Legend Biotech Corp. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which engages in the discovery and development of novel cell therapies for oncology | Health Technology |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops orally administered toll-like receptor for cancer immunotherapy | Commercial Services |
Akero Therapeutics, Inc.
 Akero Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for patients with metabolic diseases | Health Technology |
Invivyd, Inc.
 Invivyd, Inc. BiotechnologyHealth Technology Develops antibody-based solutions for infectious diseases | Health Technology |
Bioqube Ventures NV
Bioqube Ventures NV Investment ManagersFinance Functions as an alternative investment manager | Finance |
Interlaken Therapeutics, Inc. |
Choisissez Zonebourse 
